The FDA approved the antiviral drug remdesivir (Veklury, Gilead) for the treatment of COVID-19 requiring hospitalization.
Remdesivir is indicated for use in adult and pediatric patients aged 12 years and older and weighing at least 40 kg (about 88 pounds) with COVID-19. The antiviral should only be administered in a hospital or health care setting capable of providing acute care comparable to inpatient hospital care.
This approval does not include the entire population that had been